T1	Participants 177 230	patients with unresectable pancreatic adenocarcinoma.
T2	Participants 243 269	Advanced pancreatic cancer
T3	Participants 686 816	Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201
T4	Participants 1026 1089	Between February 2003 and July 2005, 25 patients were enrolled.
T5	Participants 1090 1180	Nineteen patients were randomised, 9 to the intravenous and 10 to the intra-arterial arms.
